(1 - 7 from 8
)
ASCO Tepotinib - News - EMD Group
www.emdgroup.com
“Patients living with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations have limited treatment options available to them and typically face poor clinical outcomes,” said investigator Enriqueta Felip, M.D., Medical Oncologist, Vall d’Hebron Institute of Oncology (VHIO). “More than half of the patients in the ...
sorted by relevance / date